ReviewFrontiers in immunology2026
The mechanisms of regulatory T cells in the immune microenvironment of multiple myeloma and clinical significance.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple Myeloma is a malignant hematologic disorder characterized by the abnormal proliferation of clonal plasma cells. Its pathogenesis involves a variety of complex factors, with particular attention given to the immune regulatory mechanisms within the tumor microenvironment (TME). Research indicates that the immunosuppressive microenvironment provides a protective barrier for the survival and progression of MM cells. In this context, regulatory T cells (Tregs), as key immunosuppressive cells within the TME, play a crucial role in the tumor immune tolerance network. Through interactions with various immune cells and tumor-associated factors, Tregs participate in the regulation of MM-related signaling pathways and mediate tumor angiogenesis, thereby promoting immune evasion of MM cells. This review aims to explore the specific roles and clinical significance of Tregs in the immune mechanisms of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.